WEBULL
WebtradeDownload

Avient (AVNT) Could Be 12% Undervalued As Mix Limits Near Term Growth

Simply Wall St · 23h ago

Avient (AVNT) has come into focus after recent trading saw the share price close at $40.36, with short term returns under pressure even as the year-to-date move remains positive.

Recent trading in Avient reflects that pattern. The share price has eased over the past week and month; however, the 90 day share price return of 7.17% and year to date share price gain of 27.28% sit alongside a 1 year total shareholder return of 18.46%. This suggests that longer term momentum has been stronger than the latest pullback.

Compare Avient's recent pullback and longer term gains to a curated group of stocks with sturdier fundamentals using the list of solid balance sheet and fundamentals (23 results).

Avient has delivered a strong multi-year run for holders, then softened in recent weeks. Do the current fundamentals still justify fresh money at this price, or is the balance tipping toward caution?

Most Popular Narrative: 12% Undervalued

Avient's most followed valuation narrative pegs fair value at $46, above the last close of $40.36. This frames the recent pullback against a still supportive long term view built on pricing, mix and margin work.

Although growth vectors such as health care, defense and materials tied to artificial intelligence and data center buildout are gaining traction, they currently offset weakness in roughly 80% of the portfolio rather than driving broad-based expansion. This may keep overall revenue and EBITDA growth modest.

See why 0 investors see Avient as 12% undervalued.

The narrative uses an 8.07% discount rate and arrives at a fair value of $46, compared with the current share price of $40.36 and a Street price target cluster around $50.86. That implies about a 12% gap between the narrative value and where Avient trades now, even before considering the higher targets from more optimistic analysts.

Under this view, the key swing factor is mix. Faster growing areas such as health care materials, defense exposure and products tied to high performance computing and data centers are described as gaining traction but still represent less than one fifth of the portfolio, which limits their ability to shift overall revenue and earnings quickly.

At the same time, the narrative points to management actions that could support the case for Avient's valuation, including targeted productivity initiatives and portfolio optimization aimed at improving margins, as well as consistent cash generation that is being used to reduce debt. The question for investors is how much of that execution is already reflected in the current $40.36 price versus the $46 fair value anchor.

Result: Fair Value of $46 (UNDERVALUED)

Still, Avient could invalidate this cautious fair value story if high growth areas like health care and defense scale faster, or if productivity gains flow more cleanly to earnings.

Find out about the key risks to this Avient narrative.

Next Steps

Mixed signals on Avient's value case can be useful. Act while the numbers are fresh and pressure test the bull and bear angles by reviewing the 6 key rewards and 2 important warning signs.

Looking for more Avient investment ideas?

If Avient has sharpened your thinking, do not stop here. Broaden your watchlist with focused stock ideas built from clear fundamentals and transparent data.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.